Lupin gets USFDA nod for generic schizophrenia drug
New Delhi: Drug maker Lupin Monday said it has received approval from the US health regulator to market Lurasidone Hydrochloride tablets, used in the treatment of schizophrenia, in the American market.
The company said it has received approval from the US Food and Drug Administration (FDA) to market its product, which is a generic version of Sunovion Pharmaceuticals Inc's Latuda tablets, in strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, Lupin said in a regulatory filing.
Read Also: Lupin receives FDA approval for Lurasidone Hydrochloride Tablets
The drug is indicated for conditions like schizophrenia and bipolar depression.
As per IQVIA MAT September 2018 data, Latuda Tablets had sales of around USD 3,217.3 million in the US market.
Lupin shares were trading 0.38 per cent down at Rs 825.65 on the BSE.
Read Also: Lupin and AbbVie announces the partnership to develop, commercialize Novel Oncology Drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd